- ISIN
- US92337F1075
- CUSIP
- 92337F107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 30, 2013
Highlights
- Market Cap
- $3.70B
- Enterprise Value
- $3.44B
- EPS (TTM)
- $1.41
- PE Ratio
- 32.79
- PEG Ratio
- 0.20
- Total Revenue (TTM)
- $561.90M
- Gross Profit (TTM)
- $405.67M
- EBITDA (TTM)
- $126.58M
- Year Range
- $23.35 - $60.91
- Target Price
- $57.83
- ROA (TTM)
- 7.70%
- ROE (TTM)
- 8.25%
- Avg. Volume (1M)
- 1M
- Avg. Volume Value (1M)
- $68.47M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
VCYT Performance Chart
Veracyte, Inc. (VCYT) is up 10.0% since the beginning of the year. At $46 per share, VCYT is trading 24.0% below its 52-week high of $61. Investors who bought $1,000 worth of VCYT shares 5 years ago would now be looking at an investment worth $1,040.
Loading charts...
Compare this symbol against anything
Returns By Period
Veracyte, Inc. (VCYT) has returned 10.02% so far this year and 95.94% over the past 12 months. Looking at the last ten years, VCYT has achieved an annualized return of 25.08%, outperforming the S&P 500 Index benchmark, which averaged 13.26% per year.
Veracyte, Inc.
- 1D
- -22.52%
- 1M
- -18.85%
- 6M
- 21.64%
- YTD
- 10.02%
- 1Y
- 95.94%
- 3Y*
- 19.65%
- 5Y*
- 0.78%
- 10Y*
- 25.08%
- ALL TIME*
- 10.48%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
VCYT Monthly Returns History
Based on dividend-adjusted daily data since Oct 30, 2013, VCYT's average daily return is +0.11%, while the average monthly return is +2.26%. At this rate, an investment would double in approximately 2.6 years.
Historically, 49% of months were positive and 51% were negative. The best month was Nov 2020 with a return of +57.3%, while the worst month was Sep 2015 at -50.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.
On a daily basis, VCYT closed higher 49% of trading days. The best single day was Oct 31, 2018 with a return of +28.5%, while the worst single day was Jul 31, 2026 at -22.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.55% | -3.91% | -11.97% | 2.20% | 40.77% | 26.74% | -21.13% | 10.02% | |||||
| 2025 | 14.85% | -23.57% | -14.70% | 2.87% | -12.75% | 1.58% | -13.02% | 29.05% | 13.15% | 5.10% | 31.21% | -11.07% | 6.31% |
| 2024 | -9.05% | -5.88% | -5.90% | -11.69% | 6.03% | 4.43% | 10.75% | 31.46% | 7.89% | -0.88% | 27.30% | -7.80% | 43.95% |
| 2023 | 5.90% | -2.07% | -9.39% | 1.52% | 14.31% | -1.58% | 7.77% | -3.83% | -15.42% | -7.21% | 23.55% | 7.46% | 15.93% |
| 2022 | -26.19% | -8.58% | -0.83% | -25.75% | -14.12% | 13.20% | 32.36% | -22.55% | -18.63% | 21.14% | 37.94% | -14.46% | -42.40% |
| 2021 | 15.86% | 2.40% | -7.42% | -7.44% | -21.51% | 2.38% | 11.46% | 7.97% | -3.45% | 3.08% | -13.37% | -0.68% | -15.82% |
Benchmark Metrics
Veracyte, Inc. has an annualized alpha of 8.97%, beta of 1.56, and R2 of 0.19 versus S&P 500 Index. Calculated based on daily prices since October 30, 2013.
- This stock participated in 147.84% of S&P 500 Index downside but only 142.43% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.19 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 8.97%
- Beta
- 1.56
- R²
- 0.19
- Upside Capture
- 142.43%
- Downside Capture
- 147.84%
Return for Risk
Risk / Return Rank
VCYT ranks 84 for risk / return — above 84% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Veracyte, Inc. (VCYT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VCYT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.08 | ||
| Sortino ratioReturn per unit of downside risk | +0.42 | ||
| Omega ratioGain probability vs. loss probability | 1.32 | 1.25 | +0.06 |
| Calmar ratioReturn relative to maximum drawdown | 2.49 | 2.00 | +0.48 |
| Martin ratioReturn relative to average drawdown | 5.48 | 8.49 | -3.01 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Veracyte, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Veracyte, Inc. was 81.19%, occurring on Oct 20, 2022. The portfolio has not yet recovered.
The current Veracyte, Inc. drawdown is 43.08%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-81.19%Oct 2022 | 1y 8mo | — | 5y 5moFeb 2021 - now | Bear market2022 |
-75.54%Mar 2016 | 2y 4d | 2y 10mo | 4y 10moMar 2014 - Feb 2019 | — |
-47.85%Mar 2020 | 7mo 29d | 4mo 1d | 12moJul 2019 - Jul 2020 | COVID crash2020 |
-23.50%Jan 2021 | 27d | 29d | 1mo 26dDec 2020 - Feb 2021 | — |
-19.06%Oct 2020 | 11d | 7d | 18dOct 2020 - Nov 2020 | — |
Drawdown Indicators
| VCYT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -81.19% | -56.78% | -24.41% |
Max Drawdown (1Y)Largest decline over 1 year | -39.23% | -9.10% | -30.13% |
Max Drawdown (3Y)Largest decline over 3 years | -50.09% | -18.90% | -31.19% |
Max Drawdown (5Y)Largest decline over 5 years | -71.54% | -25.43% | -46.11% |
Max Drawdown (10Y)Largest decline over 10 years | -81.19% | -33.92% | -47.27% |
Current DrawdownCurrent decline from peak | -43.08% | -1.58% | -41.50% |
Average DrawdownAverage peak-to-trough decline | -48.14% | -10.70% | -37.44% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.77% | 2.14% | +15.63% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Veracyte, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Veracyte, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for VCYT, comparing it with other companies in the Biotechnology industry. Currently, VCYT has a P/E ratio of 32.8. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for VCYT compared to other companies in the Biotechnology industry. VCYT currently has a PEG ratio of 0.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for VCYT relative to other companies in the Biotechnology industry. Currently, VCYT has a P/S ratio of 6.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for VCYT in comparison with other companies in the Biotechnology industry. Currently, VCYT has a P/B value of 2.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with VCYT
Add Veracyte, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with VCYT